Reference: 1. BLINCYTO® (blinatumomab) prescribing
information, Amgen. 2. Litzow MR, Sun Z, Mattison RJ, et al.
Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults.
N Engl J Med. 2024;391:320-333. 3. Gupta S, Rau RE, Kairalla JA,
et al. Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in
children. N Engl J Med. 2025;392:875-891.
References: 1. BLINCYTO® (blinatumomab) medication guide,
Amgen. 2. National Cancer Institute. Common terminology criteria for
adverse events (CTCAE) version 4.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v4_Quick_Reference_8.5x11.pdf. Accessed April 4,
2026. 3. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine
release syndrome. J Immunother Cancer. 2018;6:56.
4. BLINCYTO® (blinatumomab) prescribing information, Amgen.
5. Lee DW, Santomasso BD, Locke FL,
et al. ASTCT consensus grading for cytokine
release syndrome and neurologic toxicity associated with immune effector
cells. Bio Blood Marrow Transport. 2019;25:625-638.
References: 1. BLINCYTO® (blinatumomab) prescribing
information, Amgen. 2. National Cancer Institute. NCI dictionary of
cancer terms. https://www.cancer.gov/publications/dictionaries/cancer-terms.
Accessed April 17, 2026. 3. BLINCYTO® (blinatumomab)
medication guide, Amgen.
References: 1. BLINCYTO® (blinatumomab) prescribing
information, Amgen. 2. BLINCYTO® (blinatumomab) medication
guide, Amgen.
References: 1. BLINCYTO® (blinatumomab) prescribing
information, Amgen. 2. Nagorsen D, Baeuerle PA. Immunomodulatory
therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell
Res. 2011;317:1255-1260. 3. BLINCYTO® (blinatumomab)
medication guide, Amgen. 4. National Cancer Institute. NCI dictionary
of cancer terms.
https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed April
17, 2026. 5. Brüggemann M, Gökbuget N, Kneba M. Acute lymphoblastic
leukemia: monitoring minimal residual disease as a therapeutic principle.
Semin Oncol. 2012;39:47-57.
References: 1. BLINCYTO® (blinatumomab)
prescribing information, Amgen. 2. National Cancer Institute. NCI
dictionary of cancer terms.
https://www.cancer.gov/publications/
dictionaries/cancer-terms.
Accessed April 17, 2026. 3. Children’s Hospital of Philadelphia. Acute
Lymphoblastic Leukemia (ALL).
https://www.chop.edu/conditionsdiseases/acute-
lymphoblastic-leukemia-all.
Accessed April 17, 2026. 4. Brüggemann M, Gökbuget N, Kneba M. Acute
lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic
principle. Semin Oncol. 2012;39:47-57. 5. Litzow MR, Sun Z,
Mattison RJ, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia
in adults. N Engl J Med.
2024;391:320-333.
6. Gupta S, Rau RE, Kairalla JA, et al. Blinatumomab in standard-risk
B-cell acute lymphoblastic leukemia in children. N Engl J Med.
2025;392:875-891. 7. Nagorsen D, Baeuerle PA. Immunomodulatory therapy
of cancer with T cell-engaging BiTE antibody blinatumomab.
Exp Cell Res. 2011;317:1255-1260. 8. BLINCYTO®
(blinatumomab) medication guide, Amgen.